For Patients: VACO Index COVID-19 Mortality Risk

ورودی‌های بالینی بیمار

حداقل ۲۰ — حداکثر ۱۱۵ • واحد: years

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
mortality risk
—percentage
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Lower Risk0–8.7
  • Moderate Risk8.8–16
  • High Risk16.1–21.2
  • Extreme Risk21.3–100
Direct Clinical Answer

The For Patients: VACO Index COVID-19 Mortality Risk calculates predicting invasive bacterial infection probability and quantifying systemic host response to sepsis. Key inputs include age. Scores guide administering empiric broad-spectrum antimicrobial regimens, infectious source control, and isolation protocols. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Estimates 30-day mortality risk after COVID-19 infection using pre-existing health conditions and demographics. Developed by researchers from Yale University and VA Connecticut Healthcare System in collaboration with the US Department of Health and Human Services.

Clinical Indication

The For Patients: VACO Index COVID-19 Mortality Risk is indicated for bedside clinical practice to support Estimates 30-day mortality risk after COVID-19 infection using pre-existing health conditions and demographics. Developed by researchers from Yale University and VA Connecticut Healthcare System in collaboration with the US Department of Health and Human Services.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with suspected sepsis, meningitis, pneumonia, COVID-19, opportunistic infections, or fever of unknown origin. Clinical application is indicated across Infectious disease services, septic shock bays, febrile illness clinics, and isolation units.

Limitations & Contraindications

Timely administration of empiric antibiotic therapy in suspected septic shock must never be delayed for score tabulation.

Clinical Pearls & Action Plan

Blood and site-specific microbiological cultures should be secured prior to administering broad-spectrum antimicrobials.

Formula & Variables:

Uses age-specific coefficients, sex coefficients, and Charlson Comorbidity Index points with interaction terms. Final risk = exp(coefficient_sum) / (1 + exp(coefficient_sum))

Input Parameters

NameTypeRequiredDescription
ageintegerYesPatient age in years(years)
sexstringYesPatient biological sex
diabetesstringYesDiabetes mellitus status and severity (0-2 points)
chronic_pulmonary_diseasestringYesChronic pulmonary disease status (0-1 point)
renal_diseasestringYesKidney/renal disease status and severity (0-2 points)
peripheral_vascular_diseasestringYesPeripheral vascular disease status (0-1 point)
congestive_heart_failurestringYesCongestive heart failure status (0-1 point)
dementiastringYesDementia status (0-1 point)
cancerstringYesCancer status and severity (0-6 points)
cerebrovascular_accidentstringYesStroke/cerebrovascular accident history (0-1 point)
liver_diseasestringYesLiver disease status and severity (0-3 points)
myocardial_infarctionstringYesMyocardial infarction (heart attack) history (0-1 point)
peptic_ulcer_diseasestringYesPeptic ulcer disease history (0-1 point)
paralysisstringYesParalysis status (0-1 point)
aidsstringYesAIDS/HIV status (0-6 points)
rheumatologic_diseasestringYesRheumatologic disease status (0-1 point)

Score Interpretation & Guidance

RangeStageDescription
0–8.7Lower RiskLower risk of 30-day mortality
8.8–16Moderate RiskModerate risk of 30-day mortality
16.1–21.2High RiskHigh risk of 30-day mortality
21.3–100Extreme RiskExtreme risk of 30-day mortality

Evidence-Based References (EBM)

  • Justice AC, Freiburg MS, Lopez-Class M, et al. Patient-facing COVID-19 risk tool. Developed in collaboration with US Department of Health and Human Services. Yale University and VA Connecticut Healthcare System; 2020.
  • King JT Jr, Yoon JS, Rentsch CT, et al. Development and validation of a 30-day mortality index based on pre-existing medical administrative data from 13,323 COVID-19 patients: The Veterans Health Administration COVID-19 (VACO) Index. PLoS One. 2020;15(11):e0241825.
  • Rentsch CT, Kidwai-Khan F, Tate JP, et al. Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study. PLoS Med. 2020;17(9):e1003379.

Related calculators